Detailed data confirm benefits of Threshold's hypoxia-targeted pancreatic cancer drug
This article was originally published in Scrip
Executive Summary
Threshold Pharmaceuticals has reported detailed results from the Phase IIb trial of its hypoxia-targeted drug candidate, TH-302, in pancreatic cancer, confirming earlier reported findings.